Germany | BCH-LAW-DE-262236 | Biosafety Law, Regulation, Guidelines and Agreements | Biosafety Clearing-House

BCH-LAW-DE-262236-1   |   PDF   |   Print   |  

Biosafety Law, Regulation, Guidelines and Agreements (LAW)

last updated: 01 Nov 2022
General Information
Recommendation of the ZKBS for the risk assessment of the recombinant Adenovirus Ad26.COVS1 according to § 5 paragraph 1 GenTSV
Legislative details
National / Federal
Ad26.COVS1 is a replication-defective human adenovirus of serotype 26 (Ad26) that contains the Severe acute respiratory syndrome coronavirus (SARS-CoV-2) spike protein gene and is used as a vaccine against SARS-CoV-2. Ad26 belongs to the species Human mastadenovirus D. Ad26 is assigned to risk group 2.
According to § 5 paragraph 1 GenTSV in conjunction with the criteria in Annex I GenTSV, the recombinant adenovirus Ad26.COVS1 as a genetically modified organism is assigned to risk group 1.
01 Jul 2020
Regulatory contact information
Additional Information
The Central Committee on Biological Safety (ZKBS) is an expert scientific committee made up of 20 members and 20 deputy members, who represent different specialist areas or spheres of corporate interest. Its offices are based at the Federal Office of Consumer Protection and Food Safety (BVL). Its members and deputy members are appointed by the Federal Ministry for Food and Agriculture (Bundesministerium für Ernährung und Landwirtschaft, BMEL) for three years. The ZKBS evaluates GMOs for possible risk potential, assigns genetic engineering operations to a biosafety level and recommends suitable safety measures. The german federal states obtain ZKBS position statements for genetic engineering operations in safety categories 3 and 4 and for operations in a lower safety category, whose classification is not clear. The ZKBS also evaluates approval applications for releases and for the placing of GMOs on the market and also issues a report to the BVL. An activity report is published annually.